ADDISON, Texas, Dec. 2, 2015 /PRNewswire/ -- ULURU
Inc. (OTCQB: ULUR) today announced the resignation of
Jeffrey B. Davis as a Director of
the Company, effective December 1,
2015.
Mr. Davis has served as a Director of the Company since
March 2006 and also as Chairman of
the Company's Audit Committee. Bradley J. Sacks, Chairman of the Board of
Directors, stated, "We thank Jeff for his service and contributions
to the Company. The Board of Directors continues to
re-evaluate the Company's business plan, cost structure, sales
process, and capital structure with the intent of identifying
solutions that will enhance shareholder value."
About ULURU Inc.:
ULURU Inc. is a specialty
pharmaceutical company focused on the development of a portfolio of
wound management and oral care products to provide patients and
consumers improved clinical outcomes through controlled delivery
utilizing its innovative Nanoflex™ Aggregate technology and
OraDisc™ transmucosal delivery system. For further
information about ULURU Inc., please visit our website at
www.ULURUinc.com. For further information about Altrazeal®,
please visit www.Altrazeal.com.
ULURU Inc. (OTCQB: ULUR) trades on the OTCQB Venture stage
marketplace for early stage and developing U.S. and international
companies. Companies are current in their reporting and undergo an
annual verification and management certification process. Investors
can find Real-Time quotes and market information for the company on
www.otcmarkets.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended, including but not limited to statements
about potential changes to the Company's business plan, cost
structure, and other matters, and the transformation and future of
the Company. These statements are subject to numerous risks and
uncertainties, including but not limited the risks that the Company
will be unable to obtain the financial resources necessary to
improve its sales or other aspects of its business, will be unable
to identify and attract directors, and will be unable to reduce
costs or improve capital structure. Additional risk factors
detailed in the Company's Annual Report on Form 10-K for the year
ended December 31, 2014, and other
reports filed by us with the Securities and Exchange
Commission.
Contact: Company
Helmut Kerschbaumer
Interim President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/uluru-inc-announces-resignation-of-director-300187228.html
SOURCE ULURU Inc.